A new priority review was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) on January 12, 2025, entitled “Mikhail ‘Misha’ Blagosklonny’s enduring legacy in geroscience: the hyperfunction theory and the therapeutic potential of rapamycin.”
Aging (Aging-US) Authors
Dennis Mangan and Dr. Mikhail Blagosklonny discuss how Dr. Blagosklonny’s cancer research led him to the study of aging, whether rapamycin is the most important anti-aging intervention currently available, his skepticism about metformin as an anti-aging drug, and more.
PRESS RELEASE: Dr. Mikhail Blagosklonny published a new review paper in Aging (Aging-US), entitled, “Hallmarks of cancer and hallmarks of aging.”